Table 3.

Ongoing clinical trials of paxlovid

Studies	Drug participants	Trial phase	Participants type and/or number of participants	Number of participants	Status
NCT04962022[19]	Drug: PF-07321332/ritonavir Drug: Itraconazole	1	Healthy participants	12	Recruitment completed
NCT04962230[20]	Drug: PF-07321332/ritonavir Drug: Carbamazepine Drug: PF 07321332/ritonavir	1	Healthy participants	12	Recruitment completed
NCT04756531[21]	Drug: PF-07321332 different dose 1, 2 and 3 Drug: PF-07321332 dose 4 Drug: PF-07321332 dose 5 Drug: PF-07321332 dose 4 or placebo (fed)	1	Healthy participants	70	Recruitment completed
NCT05064800[22]	Drug: Dabigatran Drug: PF-07321332/ritonavir + dabigatran Drug: Ritonavir+dabigatran	1	Healthy participants	24	Recruitment completed
NCT05005312[23]	Drug: PF-07321332 Drug: Ritonavir	1	Hepatic impairment	17	Recruitment completed
NCT05032950[24]	Drug: Midazolam Drug: PF-07321332/ritonavir + Midazolam Drug: Ritonavir + midazolam	1	Healthy participants	12	Recruitment completed
NCT05047601[25]	Drug: PF-07321332 Drug: Placebo for PF-07321332 Drug: Placebo for ritonavir Drug: Ritonavir	3	Asymptomatic household contacts of symptomatic COVID-19 patients	2880	Recruitment ongoing
NCT05341609[26]	Drug: JT001 Drug: Paxlovid	Phase 3	Mild-to-moderate COVID-19	864	Recruiting
NCT04381936 (RECOVERY)[27]	Drug: Lopinavir-Ritonavir Drug: Corticosteroid Drug: Hydroxychloroquine Drug: Azithromycin Biological: Convalescent plasma Drug: Tocilizumab Biological: Immunoglobulin Drug: Synthetic neutralizing antibodies Drug: Aspirin Drug: Colchicine Drug: Baricitinib Drug: Anakinra Drug: Dimethyl fumarate Drug: High-dose corticosteroid Drug: Empagliflozin Drug: Sotrovimab Drug: Molnupiravir Drug: Paxlovid	Phase 2 Phase 3	Severe acute respiratory syndrome	50,000	Recruiting
NCT05263908[28]	Nirmatrelvir/ritonavir (paxlovid pack)	Case only, prospective study	The subjects who have been treated with paxlovid pack for the first time	3300	Not recruiting